153 related articles for article (PubMed ID: 16314952)
1. Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
Duntsch C; Divi MK; Jones T; Zhou Q; Krishnamurthy M; Boehm P; Wood G; Sills A; Moore BM
J Neurooncol; 2006 Apr; 77(2):143-52. PubMed ID: 16314952
[TBL] [Abstract][Full Text] [Related]
2. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
López-Valero I; Torres S; Salazar-Roa M; García-Taboada E; Hernández-Tiedra S; Guzmán M; Sepúlveda JM; Velasco G; Lorente M
Biochem Pharmacol; 2018 Nov; 157():275-284. PubMed ID: 30125556
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
Recht LD; Salmonsen R; Rosetti R; Jang T; Pipia G; Kubiatowski T; Karim P; Ross AH; Zurier R; Litofsky NS; Burstein S
Biochem Pharmacol; 2001 Sep; 62(6):755-63. PubMed ID: 11551521
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
Massi P; Vaccani A; Ceruti S; Colombo A; Abbracchio MP; Parolaro D
J Pharmacol Exp Ther; 2004 Mar; 308(3):838-45. PubMed ID: 14617682
[TBL] [Abstract][Full Text] [Related]
5. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
6. Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Kang GS; Wang XD; Mohler ML; Kirichenko OV; Patil R; Orr WE; Miller DD; Geisert EE
Anticancer Drugs; 2008 Oct; 19(9):859-70. PubMed ID: 18766000
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233.
Gurley SN; Abidi AH; Allison P; Guan P; Duntsch C; Robertson JH; Kosanke SD; Keir ST; Bigner DD; Elberger AJ; Moore BM
J Neurooncol; 2012 Nov; 110(2):163-77. PubMed ID: 22875710
[TBL] [Abstract][Full Text] [Related]
8. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Pollack IF; Kawecki S; Lazo JS
J Neurosurg; 1996 Jun; 84(6):1024-32. PubMed ID: 8847567
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug].
Shi MG; Huang Q; Dong J; Sun ZF; Lan Q
Ai Zheng; 2002 Oct; 21(10):1090-4. PubMed ID: 12508650
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
11. Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Emerich DF; Winn SR; Bartus RT
Cell Transplant; 2002; 11(1):47-54. PubMed ID: 12095219
[TBL] [Abstract][Full Text] [Related]
12. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
13. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
[TBL] [Abstract][Full Text] [Related]
14. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
15. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors.
Zhang RX; Dougherty DV; Rosenblum ML
Chin Med J (Engl); 1990 Aug; 103(8):658-65. PubMed ID: 2122945
[TBL] [Abstract][Full Text] [Related]
16. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis.
Lorente M; Carracedo A; Torres S; Natali F; Egia A; Hernández-Tiedra S; Salazar M; Blázquez C; Guzmán M; Velasco G
Glia; 2009 Oct; 57(13):1374-85. PubMed ID: 19229996
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, DNA binding studies and evaluation of anticancer potential of novel substituted biscarbazole derivatives against human glioma U87 MG cell line.
Kumar N; Lal N; Nemaysh V; Luthra PM
Bioorg Chem; 2020 Jul; 100():103911. PubMed ID: 32502918
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.
Fan CH; Ting CY; Liu HL; Huang CY; Hsieh HY; Yen TC; Wei KC; Yeh CK
Biomaterials; 2013 Mar; 34(8):2142-55. PubMed ID: 23246066
[TBL] [Abstract][Full Text] [Related]
19. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
20. Trans-4-lodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo.
Sasayama T; Tanaka K; Mizukawa K; Kawamura A; Kondoh T; Hosoda K; Kohmura E
J Neurooncol; 2007 Nov; 85(2):123-32. PubMed ID: 17530176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]